News

FDA advisory committee recommends approval of gout drug lesinurad, with caveats


 

References

The FDA is not obligated to follow the recommendations of its advisory committee panels.

jevans@frontlinemedcom.com

Pages

Recommended Reading

Up to 90% of gout hospitalizations might be preventable
MDedge Rheumatology
Court allows generic colchicine to enter market
MDedge Rheumatology
Gout may lower Alzheimer’s risk
MDedge Rheumatology
Gout management best practices require getting around misconceptions
MDedge Rheumatology
Gout increases risk of vascular disease, especially for women
MDedge Rheumatology
No causal effect found between high uric acid concentrations and diabetes
MDedge Rheumatology
EULAR: Panel targets six rheumatic disease comorbidities
MDedge Rheumatology
New ACR/EULAR gout classification criteria offer better sensitivity, specificity
MDedge Rheumatology
Aspirin, hydrochlorothiazide okay in gout
MDedge Rheumatology
Gout treatment lore doesn’t hold up to evidence
MDedge Rheumatology